Skip to content
Disclosery

Column Group LLC

Follow

13F filer, CIK 1833486, San Francisco, CA

Column Group LLC reported $82,793,614 across 5 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-051393

Period
2025-12-31
Reported value
$82.8M
Holdings
5
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
Surrozen, Inc.added+351,577$7.95M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RAPT THERAPEUTICS INCreduced-9,805-$332K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001193125-26-051393, largest first. % of portfolio is the value over $82,793,614, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
Surrozen, Inc.Surrozen, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 810,088 shares; 2024Q4: 810,088 shares; 2025Q1: 1,499,773 shares; 2025Q2: 1,499,773 shares; 2025Q3: 1,499,773 shares; 2025Q4: 1,851,350 shares 1,851,350$41.8M50.54%+351,577
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,540,777 shares; 2024Q4: 3,540,777 shares; 2025Q1: 3,540,777 shares; 2025Q2: 3,540,777 shares; 2025Q3: 3,540,777 shares; 2025Q4: 3,540,777 shares 3,540,777$29M34.98%0Timeline
TNYATENAYA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 9,400,290 shares; 2024Q4: 9,400,290 shares; 2025Q1: 9,400,290 shares; 2025Q2: 9,400,290 shares; 2025Q3: 9,400,290 shares; 2025Q4: 9,400,290 shares 9,400,290$6.69M8.08%0Timeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,680,621 shares; 2024Q4: 1,328,613 shares; 2025Q1: 1,328,613 shares; 2025Q2: 1,328,613 shares; 2025Q3: 166,075 shares; 2025Q4: 156,270 shares 156,270$5.29M6.39%-9,805
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 46 shares; 2024Q4: 46 shares; 2025Q1: 46 shares; 2025Q2: 46 shares; 2025Q3: 46 shares; 2025Q4: 46 shares 46$3.66K<0.01%0Timeline

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-051393 base2026-02-13acceptance time not in the bulk data set